- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03744676
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, multicenter, Phase 2 study to assess the safety and antitumor activity in adult patients with relapsed or refractory B-cell non-Hodgkin Lymphoma when administered with lisocabtagene maraleucel (JCAR017) in the outpatient setting.
Upon the successful product generation of lisocabtagene maraleucel, subjects will enter the treatment phase of the study. Treatment will include lymphodepleting chemotherapy followed by lisocabtagene maraleucel administration. Subjects will then enter the post-treatment follow-up phase of the study and will be followed for approximately 24 months for safety, disease status, health-related quality of life (HRQoL), and survival. Long-term follow-up will continue under a separate long-term follow-up protocol, per health regulatory authority guidelines, currently up to 15 years after the last lisocabtagene maraleucel administration.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Local Institution - 0057
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Local Institution - 0060
-
-
Florida
-
Miami, Florida, United States, 33176
- Local Institution - 0089
-
Orlando, Florida, United States, 32804
- Local Institution - 0081
-
-
Indiana
-
Indianapolis, Indiana, United States, 46237
- Local Institution - 0065
-
-
Kansas
-
Wichita, Kansas, United States, 67124
- Local Institution - 0069
-
-
Kentucky
-
Louisville, Kentucky, United States, 40207
- Local Institution - 0064
-
-
Michigan
-
Southfield, Michigan, United States, 48075
- Local Institution - 0101
-
-
New Jersey
-
East Brunswick, New Jersey, United States, 08816
- Local Institution - 0052
-
Morristown, New Jersey, United States, 07962
- Local Institution - 0066
-
-
New York
-
Albany, New York, United States, 12208
- Local Institution - 0041
-
-
Ohio
-
Cincinnati, Ohio, United States, 45236
- Local Institution - 0039
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- Local Institution - 0098
-
Portland, Oregon, United States, 97213
- Local Institution - 0051
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17604
- Lancaster General Hospital
-
-
South Carolina
-
Greenville, South Carolina, United States, 29615
- Local Institution - 0037
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Local Institution - 0063
-
-
Texas
-
Dallas, Texas, United States, 75230
- Local Institution - 0097
-
San Antonio, Texas, United States, 78229
- Local Institution - 0061
-
Temple, Texas, United States, 76508
- Baylor Scott and White Health
-
Tyler, Texas, United States, 75702
- Local Institution - 0096
-
-
Utah
-
Salt Lake City, Utah, United States, 84143
- Local Institution - 0074
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Local Institution - 0036
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years at the time of consent
- Relapsed or refractory B-cell NHL of the following histologies: diffuse large B cell lymphoma (DLBCL) not otherwise specified; includes biopsy-confirmed transformed DLBCL from indolent histologies, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology, primary mediastinal B-cell lymphoma(PMBCL), and follicular lymphoma Grade 3B. Subjects must have been treated with an anthracycline and rituximab (or other CD20-targeted agent) and have relapsed or refractory disease after at least 2 systemic lines of therapy for DLBCL or after auto-HSCT.
- Positron-emission tomography-positive disease by Lugano Classification
- Eastern Cooperative Oncology Group performance status of 0 to 1
- Adequate bone marrow, renal, hepatic, pulmonary, cardiac organ function
- Adequate vascular access for leukapheresis procedure
- Subjects who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on a biopsy since completing the prior CD19-targeted therapy
- Subjects must agree to use appropriate contraception.
Exclusion Criteria:
- Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study)
- History of prior allogeneic hematopoietic stem cell transplant
- Treatment with alemtuzumab within 6 months of leukapheresis, or treatment with fludarabine or cladribine within 3 months of leukapheresis
- History of another primary malignancy that has not been in remission for at least 2 years.The following are examples of exceptions from the 2-year limit: nonmelanoma skin cancer, definitively-treated stage 1 solid tumor with a low risk of recurrence, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on a Papanicolau smear.
- Active hepatitis B or hepatitis C infection at the time of screening
- History of or active human immunodeficiency virus infection at the time of screening
- Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate anti-infection treatment at the time of leukapheresis or lisocabtagene maraleucel administration
- Presence of acute or chronic graft-versus-host disease
- History of clinically significant cardiac conditions within the past 6 months
- History or presence of clinically relevant CNS pathology such as epilepsy/seizure, paresis, aphasia, stroke, cerebral edema, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
- Pregnant or nursing women
- Subject does not meet protocol-specified washout periods for certain prior treatments
- Prior CAR T-cell or other genetically modified T-cell therapy
- Progressive vascular tumor invasion, thrombosis, or embolism
- Venous thrombosis or embolism not managed on stable regimen of anticoagulation
- Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lisocabtagene maraleucel
Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of lisocabtagene maraleucel.
During lisocabtagene maraleucel production, subjects may receive low-dose chemotherapy for disease control.
Upon successful generation of lisocabtagene maraleucel product, subjects will receive treatment which will include lymphodepleting chemotherapy followed by one dose of lisocabtagene maraleucel administered by intravenous (IV) injection.
|
lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Cytokine Release Syndrome (CRS) Adverse Events Grade ≥ 3
Time Frame: From first dose to 90 days following first dose (up to approximately 90 days)
|
Cytokine release syndrome is characterized by high fever, fatigue, nausea, headache, dyspnea, tachycardia, rigors, hypotension, hypoxia, myalgia/arthralgia, and anorexia. Incidence of Grade ≥ 3 CRS, based on the TEAE with MedDRA PT "Cytokine release syndrome," graded according to the grading scale adapted from Lee (Lee 2014). |
From first dose to 90 days following first dose (up to approximately 90 days)
|
Percentage of Participants With Neurotoxicity (NT) Adverse Events Grade ≥ 3
Time Frame: From first dose to 90 days following first dose (up to approximately 90 days)
|
NT events have also been reported and may include neurologic symptoms such as altered mental status, aphasia, altered level of consciousness, and seizures or seizure-like activity. Incidence of Grade ≥ 3 NT, defined as an Investigator-identified TEAE considered neurotoxicity related to JCAR017. |
From first dose to 90 days following first dose (up to approximately 90 days)
|
Percentage of Participants With Infection Adverse Events Grade ≥ 3
Time Frame: From first dose to 90 days following first dose (up to approximately 90 days)
|
Incidence of treatment-emergent Grade ≥ 3 infections, defined using MedDRA SOC.
|
From first dose to 90 days following first dose (up to approximately 90 days)
|
Percentage of Participants With Prolonged Grade ≥ 3 Cytopenia at Day 29.
Time Frame: At Day 29 after first treatment
|
Prolonged cytopenia is defined as the occurrence of Grade ≥ 3 cytopenia not resolved by the Day 29 visit, based on laboratory results of low hemoglobin, absolute neutrophil count decreased, and platelet count decreased.
The frequency of subjects experiencing each individual laboratory abnormality and the total number with at least 1 abnormality will be summarized, as will recovery from prolonged cytopenia after Day 29.
|
At Day 29 after first treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events
Time Frame: From first dose to 90 days following first dose (up to approximately 90 days)
|
From first dose to 90 days following first dose (up to approximately 90 days)
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities- Hematology
Time Frame: From first dose to up to 41 months
|
From first dose to up to 41 months
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities- Chemistry
Time Frame: From first dose to up to 41 months
|
From first dose to up to 41 months
|
|
Number of Participants With Adverse Events Grade ≥ 3
Time Frame: From first dose to 90 days following first dose (up to approximately 90 days)
|
From first dose to 90 days following first dose (up to approximately 90 days)
|
|
Time to Onset and Time to Resolution of Grade ≥ 3 Cytokine Release Syndrome (CRS)
Time Frame: From first dose to up to approximately 41 months
|
From first dose to up to approximately 41 months
|
|
Time to Onset and Time to Resolution of Grade ≥ 3 Neurotoxicity (NT)
Time Frame: From first dose to up to approximately 41 months
|
From first dose to up to approximately 41 months
|
|
Number of Participants Administered Tocilizumab and Corticosteroid for Management of Cytokine Release Syndrome (CRS)
Time Frame: From first dose to up to approximately 41 months
|
From first dose to up to approximately 41 months
|
|
Number of Participants Administered Tocilizumab and Corticosteroid for Management of Neurotoxicity (NT)
Time Frame: From first dose to up to approximately 41 months
|
From first dose to up to approximately 41 months
|
|
Objective Response Rate (ORR)
Time Frame: From first dose to up to approximately 41 months
|
The Percentage of participants with a best overall response (BOR) of either CR or PR based on the Lugano 2014 criteria. Disease response will be determined according to the "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" Complete response is defined as:
Partial Response is defined as:
|
From first dose to up to approximately 41 months
|
Complete Response Rate (CRR)
Time Frame: From first dose to up to approximately 41 months
|
The Percentage of participants with a best overall response (BOR) with CR based on the Lugano 2014 criteria. Disease response will be determined according to the "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" Complete response is defined as:
|
From first dose to up to approximately 41 months
|
Duration of Response (DoR) and Duration of Complete Response (DoCR)
Time Frame: From first dose to up to approximately 41 months
|
Duration of response (DOR) is defined as the time from the first documentation of response (CR or PR) after JCAR017 infusion to disease progression or death from any cause, whichever occurs first. Duration of response (DOR) if BOR is CR is defined for subjects with a BOR of CR as the time from the first documentation of response (CR or PR) after JCAR017 infusion to earlier of disease progression or death from any cause. |
From first dose to up to approximately 41 months
|
Progression Free Survival (PFS)
Time Frame: From first dose to up to approximately 41 months
|
Progression-free survival is defined as the time from infusion of JCAR017 to progressive disease or death, whichever is earlier. If a subject does not have an event for the PFS analysis, the subject will be censored. Progressive Disease is defined as:
|
From first dose to up to approximately 41 months
|
Overall Survival (OS)
Time Frame: From first dose to up to approximately 41 months
|
Overall survival is defined as the time from infusion of JCAR017 to the date of death.
For assessment of OS, data from surviving participants will be censored at the last time that the participant is known to be alive.
The OS analysis will include all available survival information from the long-term follow-up study if applicable.
|
From first dose to up to approximately 41 months
|
Area Under the Blood Concentration-time Curve From Time to Zero to 28 Days After Dosing AUC (0-28)
Time Frame: 28days after first dose
|
28days after first dose
|
|
Maximum Observed Blood Concentration (Cmax)
Time Frame: 28days after first dose
|
28days after first dose
|
|
Time of Maximum Observed Blood Concentration (Tmax)
Time Frame: 28days after first dose
|
28days after first dose
|
|
European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30
Time Frame: From Enrollment to end of follow up, approximately 26 months
|
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100.
A higher scale score represents a higher level of well-being and better ability of daily functioning.
Thus, a high score for a functional scale represents a high/healthy level of functioning; a high score for the global health status/HRQoL represents a high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatic problem.
|
From Enrollment to end of follow up, approximately 26 months
|
EuroQol Instrument EQ-5D-5L.
Time Frame: Enrollment to end of follow up, approximately 26 months
|
EQ-5D is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal.
The EQ-5D-5L consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS).
The descriptive system comprises dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression).
Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems).
|
Enrollment to end of follow up, approximately 26 months
|
Number of Intensive Care Unit (ICU) Inpatient Days and Non-ICU Inpatient Days and Reasons for Hospitalization
Time Frame: From first hospitalization to the last. Approximately 31 days
|
Length of initial ICU and non-ICU stay from liso-cel administration
|
From first hospitalization to the last. Approximately 31 days
|
Number of Participants Transfused and the Number of Transfusions Per Participant.
Time Frame: From first dose to end of treatment period approximately 24 months
|
From first dose to end of treatment period approximately 24 months
|
|
Number of Participants Requiring Growth Factor Support.
Time Frame: From first dose to end of treatment period approximately 24 months
|
From first dose to end of treatment period approximately 24 months
|
|
Number of Participants Requiring Intravenous Immunoglobulin (IVIG) Support
Time Frame: From first dose to end of treatment period approximately 24 months
|
From first dose to end of treatment period approximately 24 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 017007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Information relating to our policy on data sharing and the process for requesting data can be found at the following link:
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI); Department of Health and Human Services; Early... and other collaboratorsRecruitingColonic NeoplasmsUnited States, Canada, Australia
Clinical Trials on lisocabtagene maraleucel
-
CelgeneCompletedLymphoma, Non-HodgkinItaly, Switzerland, Austria, Belgium, France, Germany, Japan, Netherlands, Spain, United Kingdom, Finland
-
Juno Therapeutics, a Subsidiary of CelgeneActive, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, Small LymphocyticUnited States
-
Juno Therapeutics, a Subsidiary of CelgeneActive, not recruitingFollicular Lymphoma | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma | Mantle-cell LymphomaUnited States
-
Juno Therapeutics, a Subsidiary of CelgeneAvailableLymphoma, Large B-Cell, Diffuse
-
Juno Therapeutics, a Subsidiary of CelgeneCompletedLymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, NonhodgkinUnited States
-
Bristol-Myers SquibbRecruitingMultiple Myeloma | Non-Hodgkin Lymphoma | Chronic Lymphocytic LeukaemiaBelgium
-
CelgeneCompletedLymphoma, Non-HodgkinUnited States, Belgium, Germany, Japan, Netherlands, France, Sweden, Italy, Spain, Switzerland, United Kingdom, Finland
-
NeoImmuneTechRecruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-cell LymphomaUnited States
-
Patrick C. Johnson, MDAstraZenecaRecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Grade 3b Follicular Lymphoma | Refractory Aggressive B-cell Lymphomas | Aggressive B-cell NHL | De Novo or Transformed Indolent B-cell Lymphoma | DLBCL, Nos Genetic Subtypes | T Cell/Histiocyte-rich Large B-cell Lymphoma and other conditionsUnited States
-
Juno Therapeutics, Inc., a Bristol-Myers Squibb...Celgene CorporationWithdrawnLeukemia, Lymphocytic, Chronic, B-CellUnited States, Austria, Belgium, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom